Maternal highly active antiretroviral therapy reduces vertical cytomegalovirus transmission but does not reduce breast milk cytomegalovirus levels

AIDS Research and Human Retroviruses

Volumn 33, Issue 4, 2017, Pages 332-338

  Slyker, Jennifer A ^a   Richardson, Barbra ^b,c   Chung, Michael H ^a,b,d   Atkinson, Claire ^e   Ásbjörnsdóttir, Kristjana H ^b   Lehman, Dara A ^a,c   Boeckh, Michael ^c,d   Emery, Vincent ^f   Kiarie, James ^g   John Stewart, Grace ^a,b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Antiretroviral therapy; Breastmilk; Cytomegalovirus; HAART; Human immunodeficiency virus; Neonates

Indexed keywords

LAMIVUDINE; NEVIRAPINE; VIRUS DNA; ZIDOVUDINE;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BREAST FEEDING; BREAST MILK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUERPERIUM; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; ADULT; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; ISOLATION AND PURIFICATION; KENYA; NEWBORN; PHASE 2 CLINICAL TRIAL; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD; YOUNG ADULT;

EID: 85015187456     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0121     Document Type: Article

References (36)

1. Lichtner M, Cicconi P, Vita S, et al.: Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis 2015;211:178-186.
2. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD: Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004;363:2116-2121.
3. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ: Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999;73:7027-7030.
4. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ: Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998; 101:497-502.
5. Emery VC, Sabin C, Feinberg JE, Grywacz M, Knight S, Griffiths PD: Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1999;180:695-701.
6. Kovacs A, Schluchter M, Easley K, et al.: Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999;341:77-84.
7. Chandwani S, Kaul A, Bebenroth D, et al.: Cytomegalovirus infection in human immunodeficiency virus type 1- infected children. Pediatr Infect Dis J 1996;15:310-314.
8. Nigro G, Krzysztofiak A, Gattinara GC, et al.: Rapid progression of HIV disease in children with cytomegalovirus DNAemia. AIDS 1996;10:1127-1133.
9. Slyker JA, Lohman-Payne BL, John-Stewart GC, et al.: Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS 2009;23:2173-2181.
10. Gompels UA, Larke N, Sanz-Ramos M, et al.: Human cytomegalovirus infant infection adversely affects growth and development in maternally HIV-exposed and unexposed infants in Zambia. Clin Infect Dis 2012;54:434-442.
11. Richardson BA, John-Stewart G, Atkinson C, et al.: Vertical cytomegalovirus transmission from HIV-infected women randomized to formula-feed or breastfeed their infants. J Infect Dis 2016;213:992-998.
12. Slyker J, Farquhar C, Atkinson C, et al.: Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. Clin Infect Dis 2014;58:564-572.
13. Berntsson M, Dubicanac L, Tunback P, Ellstrom A, Lowhagen GB, Bergstrom T: Frequent detection of cytomegalovirus and Epstein-Barr virus in cervical secretions from healthy young women. Acta Obstet Gynecol Scand 2013; 92:706-710.
14. Lurain NS, Robert ES, Xu J, et al.: HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis 2004;190:619-623.
15. Montgomery R, Youngblood L, Medearis DN Jr.: Recovery of cytomegalovirus from the cervix in pregnancy. Pediatrics 1972;49:524-531.
16. Reynolds DW, Stagno S, Hosty TS, Tiller M, Alford CA Jr.: Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 1973;289:1-5.
17. Shen CY, Chang SF, Yen MS, Ng HT, Huang ES, Wu CW: Cytomegalovirus excretion in pregnant and nonpregnant women. J Clin Microbiol 1993;31:1635-1636.
18. Stagno S, Reynolds DW, Pass RF, Alford CA: Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980;302:1073-1076.
19. Manicklal S, van Niekerk AM, Kroon SM, et al.: Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis 2014;58:1467-1472.
20. Guibert G, Warszawski J, Le Chenadec J, et al.: Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. Clin Infect Dis 2009;48:1516-1525.
21. Frederick T, Homans J, Spencer L, et al.: The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal cytomegalovirus among HIV-infected and HIV-exposed infants. Clin Infect Dis 2012;55:877-884.
22. Chang TS, Wiener J, Dollard SC, et al.: Effect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers. AIDS 2015;29:831-836.
23. Meyer SA, Westreich DJ, Patel E, et al.: Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers. Infect Dis Obstet Gynecol 2014;2014:989721.
24. World Health Organization: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Programmatic Update. World Health Organization, Geneva, 2012.
25. Chung MH, Kiarie JN, Richardson BA, et al.: Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: A phase II randomized clinical trial. Antivir Ther 2008;13:799-807.
26. Lehman DA, Chung MH, John-Stewart GC, et al.: HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 2008;22: 1475-1485.
27. Emery S, Bodrug S, Richardson BA, et al.: Evaluation of performance of the Gen-Probe HIV type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 2000;38:2688-2695.
28. Panteleeff DD, John G, Nduati RW, et al.: Rapid method for screening dried blood samples on filter paper for HIV type 1 DNA. J Clin Microbiol 1999;37:350-353.
29. Roxby AC, Atkinson C, Asbjornsdottir K, et al.: Maternal valacyclovir and infant cytomegalovirus acquisition: A randomized controlled trial among HIV-infected women. PLoS One 2014;9:e87855.
30. Abu-Raya B, Smolen KK, Willems F, Kollmann TR, Marchant A: Transfer of maternal antimicrobial immunity to HIV-exposed uninfected newborns. Front Immunol 2016; 7:338.
31. Farquhar C, Nduati R, Haigwood N, et al.: High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005;40:494-497.
32. Hamprecht K, Witzel S, Maschmann J, et al.: Rapid detection and quantification of cell free cytomegalovirus by a highspeed centrifugation-based microculture assay: Comparison to longitudinally analyzed viral DNA load and pp67 late transcript during lactation. J Clin Virol 2003;28:303-316.
33. Yasuda A, Kimura H, Hayakawa M, et al.: Evaluation of cytomegalovirus infections transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay. Pediatrics 2003;111:1333-1336.
34. Gianella S, Redd AD, Grabowski MK, et al.: Vaginal cytomegalovirus shedding before and after initiation of antiretroviral therapy in Rakai, Uganda. J Infect Dis 2015;212: 899-903.
35. Tobian AA, Grabowski MK, Serwadda D, et al.: Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013;208:839-846.
36. National AIDS and STI Control Program (NASCOP) Kenya Ministry of Health: Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Rapid Advice. NASCOP, Kenya, 2014.